Evolution of the Average Target: Myriad Genetics, Inc.

Evolution of the Average Target - Myriad Genetics, Inc.

Evolution of the Target Price: Myriad Genetics, Inc.

Evolution of the Target Price - Myriad Genetics, Inc.

Changes in Analyst Recommendations: Myriad Genetics, Inc.

3f1a1cdf5ce3.Cwjjzu7cvvVXsUp6sQTlcDIKZXh0Tz23UdHWdTmzvgA.bWaSjYuNxLYb1SIWhmOIBnxkVTA7PXjmIYmTDXqH60FGQKz-urnYuxyJLQ~b2fb8c4bcfbe933a856e1ddd9582b6b0
09/09 UBS Adjusts Price Target on Myriad Genetics to $3.60 From $6, Keeps Neutral Rating MT
01/09 Myriad Genetics Shares Fall After Piper Sandler Downgrade MT
01/09 Piper Sandler Downgrades Myriad Genetics to Underweight From Overweight MT
24/02 UBS Adjusts Price Target on Myriad Genetics to $6 From $8, Maintains Neutral Rating MT
04/11 UBS Adjusts Myriad Genetics Price Target to $8 From $6, Maintains Neutral Rating MT
07/25/07 UBS Adjusts Price Target on Myriad Genetics to $6 From $7, Maintains Neutral Rating MT
06/25/06 Top Midday Gainers MT
22/25/22 Myriad Genetics Shares Fall After Downgrade From Scotiabank MT
21/25/21 Scotiabank Downgrades Myriad Genetics to Sector Perform From Sector Outperform, Adjusts Price Target to $6 From $20 MT
19/25/19 Morgan Stanley Cuts Price Target on Myriad Genetics to $7 From $16, Maintains Equalweight Rating MT
08/25/08 Wolfe Research Downgrades Myriad Genetics to Peer Perform From Outperform MT
07/25/07 UBS Adjusts Price Target on Myriad Genetics to $7 From $16, Maintains Neutral Rating MT
07/25/07 Wells Fargo Downgrades Myriad Genetics to Equalweight From Overweight, Adjusts Price Target to $6 From $22 MT
09/25/09 Guggenheim Downgrades Myriad Genetics to Neutral From Buy MT
13/25/13 Myriad Genetics Shares Rise After Upgrade From Piper Sandler MT
12/25/12 Piper Sandler Upgrades Myriad Genetics to Overweight From Neutral, Adjusts Price Target to $12.50 From $11.50 MT
25/25/25 UBS Adjusts Price Target on Myriad Genetics to $16 From $18, Maintains Neutral Rating MT
09/24/09 Leerink Partners Downgrades Myriad Genetics to Market Perform From Outperform, Cuts Price Target to $21 From $30 MT
18/24/18 Morgan Stanley Cuts Price Target on Myriad Genetics to $21 From $32, Keeps Equalweight Rating MT
19/24/19 Morgan Stanley Initiates Myriad Genetics at Equalweight With $32 Price Target MT
19/24/19 Morgan Stanley Initiates Myriad Genetics at Equalweight MT
28/24/28 Wells Fargo Initiates Myriad Genetics at Overweight With $35 Price Target MT
27/24/27 Scotiabank Initiates Myriad Genetics at Sector Outperform MT
13/24/13 Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating MT
29/24/29 Goldman Sachs Adjusts Myriad Genetics' Price Target to $31 From $28, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- +3.33%
+15.09%
+10.41%
+23.06%
+43.42%
+7.85%
+17.74%
+1.21%
+25.9%
+12.11%
Average +16.01%
Weighted average by Cap. +17.72%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
3.980USD
Average target price
4.112USD
Spread / Average Target
+3.33%
High Price Target
8.000USD
Spread / Highest target
+101.01%
Low Price Target
2.000USD
Spread / Lowest Target
-49.75%

Analyst Consensus Detail

Analyst consensus - Myriad Genetics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Myriad Genetics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - Myriad Genetics, Inc.
  1. Stock Market
  2. Stocks
  3. MYGN Stock
  4. Consensus Myriad Genetics, Inc.